ZWOLLE, The Netherlands, June 12, 2014 /PRNewswire/ --
Randomized Evaluation of short-term DUal antiplatelet therapy in patients with acute coronary syndrome treated with the COMBOTM Dual-Therapy StEnt
The Principal Investigators of the REDUCE trial announce the enrolment of the first patient in the REDUCE trial with the OrbusNeich COMBO Dual Therapy Stent at Isala Hospital, Zwolle, the Netherlands.
Help employers find you! Check out all the jobs and post your resume.
